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Canine NAPEPLD-associated 
models of human myelin disorders
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K. J. Ekenstedt6, E. Furrow1, E. E. Patterson1, S. R. Platt7, P. A. Kelly8, J. P. Cassidy8, G. D. 
Shelton9, K. Lucot10, D. L. Bannasch10, H. Martineau11, C. F. Muir11, S. L. Priestnall11,  
D. Henke12, A. Oevermann13, V. Jagannathan2, J. R. Mickelson1 & C. Drögemüller  2
Canine leukoencephalomyelopathy (LEMP) is a juvenile-onset neurodegenerative disorder of the CNS 
white matter currently described in Rottweiler and Leonberger dogs. Genome-wide association study 
(GWAS) allowed us to map LEMP in a Leonberger cohort to dog chromosome 18. Subsequent whole 
genome re-sequencing of a Leonberger case enabled the identification of a single private homozygous 
non-synonymous missense variant located in the highly conserved metallo-beta-lactamase domain of 
the N-acyl phosphatidylethanolamine phospholipase D (NAPEPLD) gene, encoding an enzyme of the 
endocannabinoid system. We then sequenced this gene in LEMP-affected Rottweilers and identified 
a different frameshift variant, which is predicted to replace the C-terminal metallo-beta-lactamase 
domain of the wild type protein. Haplotype analysis of SNP array genotypes revealed that the 
frameshift variant was present in diverse haplotypes in Rottweilers, and also in Great Danes, indicating 
an old origin of this second NAPEPLD variant. The identification of different NAPEPLD variants in 
dog breeds affected by leukoencephalopathies with heterogeneous pathological features, implicates 
the NAPEPLD enzyme as important in myelin homeostasis, and suggests a novel candidate gene for 
myelination disorders in people.
The classification of human leukoencephalopathies was initially based upon pathology and biochemistry and has 
been applied to disorders caused by toxic, acquired vascular, or infectious insults, as well as inherited disorders1. 
This scheme has recently been updated to a case definition of leukodystrophies that refer to 30 distinct disorders 
with wasting (dystrophy) of the brain’s white matter (leuko) and a consensus definition of heritable white matter 
disorders based on neuroimaging1,2. Interestingly, nearly half of all patients whose neuroimaging studies indicate 
white matter disease and whose clinical manifestations suggest a genetic etiology do not receive a specific diag-
nosis3. More than 60 distinct types of genetic leukoencephalopathies (gLE), a recently introduced broader term1, 
are associated with white matter lesions in the central nervous system (CNS), and in people these represent a 
heterogeneous group of disorders with both highly variable clinical and pathologic manifestations1,4. A recent 
genetic screening of 118 leukoencephalopathy-related genes in 49 patients diagnosed with gLE showed evidence 
for pathogenic variants in 40.8% of them5.
In humans, primary myelin disorders of CNS (so called white matter diseases) are caused by defects in 
myelin formation and/or maintenance and include dysmyelinating (abnormally formed myelin) diseases, 
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hypomyelinating disorders (decreased myelin production), and spongy vacuolar degeneration of myelin4. Myelin 
disorders have also been reported in miscellaneous domestic animal species including various breeds of dog6,7. 
Although infrequently seen, during the last 40 years several breed-specific forms of myelopathy in which there 
is lysis of the white matter have been described and termed leukoencephalomyelopathies (OMIA 001788-9615) 
in Afghan Hounds8, Rottweilers9–12 and Leonbergers13, or as necrotizing myelopathy in Kooiker dogs14. Affected 
dogs present clinically weak and ataxic with loss of conscious proprioception (Supplementary Video S1). Usually 
these diseases occur in young animals suggesting a hereditary basis.
As similar myelin disorders are known in people, this study aimed to identify the genetic cause of canine leu-
koencephalomyelopathy (LEMP) in Leonbergers and Rottweilers as complementary models. Herein we report 
the identification of a causative gene for both these forms of canine LEMP that represents a novel candidate gene 
for human myelin disorders such as gLE disease.
Results
Leukoencephalomyelopathy (LEMP) in Leonbergers is associated with the region of N-acyl 
phosphatidylethanolamine phospholipase D (NAPEPLD) on chromosome 18. For the GWAS 
we utilized 14 Leonberger neurological cases clinically compatible with LEMP (ages of onset 1.3–4 years), in 
which seven cases were confirmed by necropsy, and one dog also confirmed via magnetic resonance imaging 
(Supplementary Table S1). Additionally, we included 186 neurologically healthy Leonberger controls (eight years 
and older) based on prior 170k SNP array genotyping data (Fig. 1a). A genomic inflation factor (lambda) of 2.29 
indicated the presence of population stratification and possible cryptic relatedness. We performed a multidimen-
sional scaling analysis revealing no indication for clustering of cases outside the controls (Supplementary Fig. S1). 
We therefore performed an association analysis using the mixed model function that resulted in lambda dropping 
to 1.187. We obtained a highly significant association signal on chromosome 18 (Fig. 1a; pcorrected = 9.06 × 10−19). 
Haplotype analysis of the LEMP-affected Leonbergers showed a 3.3 Mb area of extended shared homozygosity 
from positions 16.6 to 19.9 Mb (Fig. 1b).
Figure 1. Positional cloning of the LEMP-associated locus in Leonbergers. (a) Manhattan plot for the GWAS 
using 14 LEMP-affected dogs and 186 control dogs is shown and indicates a signal with multiple associated 
SNPs on chromosome 18. The -log P-values for each SNP are plotted on the y-axis versus each canine autosome 
and the X chromosome on the x-axis. The red line represents the Bonferroni corrected significance threshold 
(−log (P) = 6.35). A mixed model analysis corrected for population stratification was carried out as described 
in the Methods. Inset: Corrected QQ-plot confirms that the actually observed P-values of the best associated 
markers have stronger association with the trait than expected by chance (null hypothesis, red line). (b) 
Haplotype analysis of SNP array genotypes of 14 cases and 28 carriers allowed fine mapping of the critical 
region for LEMP to a 0.9 Mb interval. Each line represents a unique haplotype. (c) The LEMP-associated region 
contains 14 loci including NAPEPLD gene.
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A missense variant in the NAPEPLD gene is associated with LEMP in Leonbergers. Whole 
genome re-sequencing (WGS) was performed on a Leonberger LEMP case homozygous for the associated haplo-
type. Subsequently, sequence variants in the mapped interval were called. The pedigree analysis (Supplementary 
Fig. S2) and the large size of the homozygous interval indicated a relatively young origin of the variant and a 
likely recessive mode of inheritance. Thus, we assumed that the causative variant should be absent from breeds 
unrelated to the Leonbergers. A total of 32 variants in the interval unique to the sequenced case remained after 
filtering against 201 control genomes of 66 different dog breeds and three wolves (Supplementary Table S2). 
Only a single variant (chr18:g.16987520 G > C) was predicted to affect the coding sequence of an annotated gene 
(Supplementary Table S3). Sanger sequencing confirmed the presence of this variant (Fig. 2a) and its nearly 
perfect association to the LEMP phenotype (Supplementary Fig. S2). This private non-synonymous variant 
Figure 2. The NAPEPLD missense variant detected in LEMP-affected Leonbergers. (a) Chromatograms 
of wild type, carrier, and an affected dog indicate the c.538 G > C variant which changes codon 180 (shown 
below). (b) The variant is located in exon 3 of canine NAPEPLD that encodes a functionally important 
domain of the NAPEPLD protein. (c) The predicted p.Ala180Pro exchange affects an evolutionary conserved 
residue. The multiple sequence amino acid alignment was done using accessions XP_005631036.1 (Canis 
lupus familiaris), NP_001116310.1 (Homo sapiens), NP_001015680.1 (Bos taurus), XP_014594420.1 (Equus 
caballus), NP_848843.1 (Mus musculus), NP_955413.1 (Rattus norwegicus), NP_001025901.1 (Gallus gallus), 
XP_002933136.1 (Xenopus tropicalis) and NP_001074082.2 (Danio rerio).
Breed Status Total
G/G (homozygous 
normal; N/N)
C/G (heterozygous; 
D/N)
C/C (homozygous 
mutant; D/D)
Leonberger
7,086 5,956 1,054* 761
Affected2 27 271
Non-affected#,2 574 486 82 6
Unknown§ 6,485 5,470 972 43
Great Danes§ 262 262
St. Bernard§ 47 47
Newfoundland§ 10 10
Entlebucher Mountain dog§ 10 10
Appenzeller Mountain dog§ 8 8
Bernese Mountain dog§ 7 7
Greater Swiss Mountain dog§ 6 6
Table 1. NAPEPLD c.538 G > C genotype frequencies in Leonbergers and 7 other related breeds. *Including 
10 obligate carriers (dam/sire of LEMP cases). #Owner reported no signs of LEMP in dogs older than 8 years. 
§Dogs without known phenotype status that were submitted for diagnostic purposes. 1Includes the two cases 
reported before13. 2Allele frequency difference p < 1.5 × 10−89.
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in the N-acyl phosphatidylethanolamine phospholipase D (NAPEPLD) gene (c.538 G > C) is located within the 
metallo-beta-lactamase domain of the encoded protein (Fig. 2b). It is predicted to alter the sequence of codon 
180 resulting in the replacement of alanine by proline (p.Ala180Pro). Multiple species amino acid sequence align-
ment showed that the wild type residue at the affected position is conserved across NAPEPLD orthologues in 
vertebrates including the zebrafish (Fig. 2c). Software-based analysis of the NAPEPLD amino acid exchange char-
acterized the variant as probably damaging (PolyPhen 2), deleterious (SIFT), pathogenic (MutPred2) or disease 
causing (Mutation Taster). An mRNA-seq experiment on a spinal cord sample of a LEMP-affected Leonberger 
was carried out and revealed no evidence for alternative splicing of NAPEPLD in comparison to a spinal cord 
sample from a control dog (not shown).
To further investigate the frequency of the NAPEPLD variant in Leonbergers, and its segregation with dis-
ease, we genotyped in total 7,086 dogs (Table 1). This includes all 200 dogs from the GWAS, two previously 
described cases13, 11 additional LEMP-affected Leonbergers, as well as 574 dogs with owner reported health 
updates indicating no neurological problems within the first eight years of life. There was a highly significant dif-
ference in NAPEPLD allele frequencies between LEMP cases and these controls using a standard chi-square test 
(p < 1.5 × 10−89). The absence of affected heterozygotes in this large cohort supports a recessive mode of inher-
itance (standard chi-square test p < 7.9 × 10−108). However, approximately 1% (6/574) of non-affected dogs at 
eight years of age were homozygous for the mutant allele, indicating reduced penetrance (Table 1). Furthermore, 
Figure 3. The NAPEPLD frameshift variant detected in LEMP-affected Rottweilers. (a) Chromatograms of 
wild type, carrier, and an affected dog indicate the c.345_346insC variant. (b,c) The schematic representation of 
the canine NAPEPLD gene indicates that the 1 bp insertion is located in exon 3 and leads to a frameshift which 
is predicted to produce a novel 186 amino acid long C-terminus of NAPEPLD and replaces the metallo-beta-
lactamase domain of the wild type protein.
Breed Status Total
wt/wt (homozygous 
normal; N/N)
ins/wt 
(heterozygous; D/N)
ins/ins (homozygous 
mutant; D/D)
Rottweiler
233 212 17 41
Affected2 4 41
Non-affected2 72 64 8
Unknown§ 157 148 9
Great Danes§ 262 238 24
St. Bernard§ 47 47
Newfoundland§ 10 10
Entlebucher Mountain dog§ 10 10
Appenzeller Mountain dog§ 8 8
Bernese Mountain dog§ 7 7
Greater Swiss Mountain dog§ 6 6
Table 2. NAPEPLD c.345_346insC genotype frequencies in Rottweilers, Great Danes and 6 other related 
breeds. §Dogs without known phenotype status that were submitted for diagnostic purposes. 1Includes the two 
cases reported before11,12. 2Allele frequency difference p < 2.4 × 10−17.
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we genotyped nearly 6,500, mostly young, Leonbergers with unknown phenotype status, that were submitted 
for diagnostic purposes, which well represents the global population of the breed. The genotype frequency of 
homozygous mutant dogs in this cohort was 0.6%. Altogether, the mutant allele frequency in the global popula-
tion of 7,086 Leonbergers was estimated as 8.5%.
Finally, the analysis of 28 heterozygous dogs carrying the LEMP-associated NAPEPLD allele identified shorter 
versions of the variant-containing haplotype due to recombination events. This enabled narrowing of the shared 
region surrounding the NAPEPLD allele on chromosome 18 to approximately 0.9 Mb (bp position 16,611,402 to 
17,559,984; Fig. 1b). This shared haplotype contains 13 annotated protein-encoding genes and one pseudogene 
(Fig. 1c).
A frameshift variant in the NAPEPLD gene is associated with LEMP in Rottweilers and also 
occurs in Great Danes. We utilized a total of four LEMP-affected Rottweilers to evaluate whether the 
NAPEPLD gene harbored possible disease-causing variants in this breed. This cohort includes the two previously 
described cases11,12 and two additional dogs (Supplementary Table S4). All four coding exons of the NAPEPLD 
gene were Sanger sequenced in the LEMP-affected Rottweilers. All were clear of the Leonberger missense variant, 
but a frameshift variant in exon 3 (c.345_346insC) was discovered in which the four LEMP-affected Rottweilers 
were homozygous (Fig. 3a). This 1 bp insertion is predicted to replace the C-terminal metallo-beta-lactamase 
domain of the wild type protein by a recoded peptide of 186 amino acids (p.Glu116ArgfsTer186) without any 
sequence similarity (Fig. 3b,c). The NAPEPLD frameshift allele (chr18: g.16987327_16987328insC) frequency 
in a population of 229 non-affected Rottweilers was 3.7% with no homozygous mutant dogs observed (Table 2). 
To confirm the focus on the NAPELD gene we performed a GWAS with 3 affected Rottweilers with passing 
SNP genotyping call rate and identified the same chromosome 18 locus (pcorrected = 7.06 × 10−15) as found in 
Leonbergers, that spanned the NAPEPLD gene (Supplementary Fig. S3). Further, WGS of an LEMP-affected 
Rottweiler confirmed the 1 bp insertion which was identified via Sanger sequencing and showed no further var-
iants in the NAPEPLD gene. We also screened related breeds for the presence of this frameshift variant and 
identified non-affected heterozygous dogs in Great Danes, and an allele frequency of 4.5% in this breed cohort 
(Table 2). This variant was not present among the 201 sequenced control genomes of 66 different dog breeds and 
three wolves (Supplementary Table S2).
Subsequent haplotype analysis of 170k SNP array genotypes revealed that the NAPEPLD frameshift variant 
was present on three diverse haplotypes in affected Rottweilers (Fig. 4a). We then genotyped additional het-
erozygous Rottweilers and Great Danes to study the haplotype diversity in a 1.5 Mb interval surrounding the 
NAPEPLD gene. This revealed a collection of extended haplotypes associated with the frameshift variant (Fig. 4a). 
Nonetheless, an identical 50 kb sub-haplotype containing segments of the canine NAPEPLD and ARMC10 genes 
was identified in all homozygous and heterozygous dogs (Fig. 4b).
Variable histopathological phenotype in NAPEPLD homozygous dogs within and across breeds. 
After variant identification we histopathologically re-evaluated eight neurologically affected Leonbergers gen-
otyped as homozygous mutant for the c.538 G > C variant, including the two previously described cases13, and 
three neurologically affected Rottweilers genotyped as homozygous mutant for the c.345_346insC variant, 
including two reported LEMP-affected dogs from Germany11 and the US12. Stained tissue sections available for 
re-evaluation varied between dogs, however clear variation in histological lesions was observed. Nine out of 
these eleven dogs had histopathological lesions compatible with LEMP (Leonberger cases L1-6 (Supplementary 
Table S1), Rottweiler cases R1-3 (Supplementary Table S4)). In all nine dogs the spinal cord was affected. 
Additionally, in four LEMP-affected dogs, of which the brain was also available, a specific pattern with lesions 
involving the spinal tract of the trigeminus, cerebellar peduncles, cerebellar medulla, pyramids, crus cerebri, 
and optic tract was observed. No lesions were present in the spinal nerve roots. Generally, the nine dogs com-
patible with LEMP suffered marked loss of myelin (Fig. 5). The myelin was replaced by numerous fibrillary and 
Figure 4. Across breed haplotype analysis in Rottweilers and Great Danes indicates an old mutation event. (a) 
Diverse haplotypes were detected exploring SNP array genotypes of four LEMP-affected Rottweilers (RO) and 
23 heterozygous carriers of the NAPEPLD frameshift variant in Rottweilers and Great Danes (GD). Each line 
represents a unique haplotype. (b) A 50 kb-sized identical haplotype in all dogs contains segments of the canine 
NAPEPLD and ARMC10 genes.
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gemistocytic astrocytes (Fig. 6). Within and around the gliotic area scattered dilated myelin sheaths containing 
gitter cells were present, and a few scattered swollen axons were observed. Minimal Wallerian-like degeneration 
was observed in areas distant from the areas of myelin loss. Lesions were predominantly bilaterally symmetrical 
(Fig. 5), although in some areas a marked asymmetry could be observed.
There was variation in severity and topography between cases. Three cases (L1, L2, and R2) exhibited lesions 
predominantly affecting the lateral corticospinal tract and encroaching on the dorsal spinocerebellar, rubrospinal 
and the lateral spinothalamic tracts as previously described. In three dogs (R1, L5, and L6) lesions were similar in 
distribution, but very severe, being characterized by severe loss of white matter with infiltration of macrophages 
and capillary prominence. In three other cases (R3, L3 and L4) the distribution was different with lesions being 
most severe in the dorsal funiculi or being more widespread. In most dogs, axonal changes were relatively mild 
Figure 5. Phenotypic variability of transverse spinal cord sections of LEMP-affected dogs. Combined luxol fast 
blue/hematoxylin & eosin stain of paraffin sections. (a) Thoracic spinal cord of a Leonberger case L1 with typical 
LEMP lesions as previously described13. Note the bilateral-symmetrical loss of myelin in the corticospinal tracts 
as indicated by the loss of the blue color. (b) Cervical spinal cord of a previously described12 Rottweiler case R1 
with similar lesions as in (a). This dog had severe white matter loss in some areas combined with axonal loss, 
infiltration by macrophages and capillary hypertrophy. (c) Thoracic spinal cord of Leonberger case L3. The 
quality of lesions is similar as in (a), but the distribution is different with lesions being most severe in the dorsal 
tracts. (d) Thoracic spinal cord of Rottweiler case R3 showing similar lesions, which are less defined and more 
widespread encroaching into lateroventral tracts.
Figure 6. Histopathology of the spinal cord of LEMP-affected dogs. Combined luxol fast blue/hematoxylin & 
eosin stain of paraffin sections. (a,b) Spinal cord sections of previously described11 Rottweiler case R2 showing 
deep blue staining of the normal myelin in an unaffected area (a) and an affected spinal cord area (b) exhibiting 
loss of blue myelin staining, vacuoles (asterisk), and large gemistocytic astrocytes (arrow). (c) Affected spinal 
cord area of the previously described Rottweiler case R112 exhibiting severe loss of blue myelin staining, 
vacuoles (asterisk), infiltration by macrophages (black arrowhead), capillary hypertrophy (brown arrowhead) 
and large gemistocytic astrocytes (arrow).
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and confined to the areas of severe myelin loss indicating a primary myelin disorder. In contrast, one Rottweiler 
case (R3) with severe white matter lesions exhibited more conspicuous axonal degeneration, and Bielschowsky 
stain revealed reduced axonal density in these areas.
Interestingly, two Leonbergers exhibited histopathological lesions not compatible with LEMP. One Leonberger 
case (L8) suffered axonal degeneration in the peripheral nerves associated with denervation atrophy of the skele-
tal muscle (Supplementary Fig. S4) compatible with Leonberger polyneuropathy15. Additionally, this dog exhib-
ited scattered axonal degeneration in the spinal cord without conspicuous myelin loss (Supplementary Fig. S4). 
The second deviating Leonberger case (L7) had no lesions in the examined spinal cord section, but a well-defined, 
plaque-like area of demyelination and gliosis in the corona radiata (Supplementary Fig. S5).
Discussion
We investigated a possible genetic basis for leukoencephalomyelopathy (LEMP) in Leonbergers and Rottweilers. 
The pathological lesions in both breeds were reported clearly to be demyelinating but the distribution, restricted 
to the white matter of brain and spinal cord, remained unclear11,13. Our studies revealed two independent 
non-synonymous variants affecting the canine NAPEPLD gene, a gene with no known role in myelination or 
myelinogenesis of oligodendrocytes.
The endocannabinoid system consists of endocannabinoids, cannabinoid receptors and enzymes, such as 
NAPEPLD, involved in the synthesis and degradation of endogenous ligands16. It is a widespread neuromod-
ulatory system which plays important roles in central nervous system development, synaptic plasticity, and the 
response to endogenous and environmental insults16. Some endocannabinoids are supposed to have a neuro-
protective function17. The NAPEPLD protein is a membrane-bound phospholipase D type enzyme that cata-
lyzes the release of N-acylethanolamine from N-acyl-phosphatidylethanolamine18, and in so doing generates 
N-arachidonoylethanolamine, a ligand of cannabinoid and vanilloid receptors19. NAPEPLD is the enzyme cata-
lyzing the production of arachidonoylethanolamine in animal tissues, and is structurally different from other 
known phospholipases D19. Nonetheless, it belongs to the zinc metallohydrolase family of the beta-lactamase 
fold, which is involved in a variety of biological events including antibiotic resistance, DNA repair and RNA 
maturation20. Several single point mutants, affecting highly conserved histidine and aspartic acid residues in the 
metallo-beta-lactamase domain involved in the binding to Zn2+, are known to be catalytically inactive or have 
reduced enzyme activity20,21. The NAPEPLD protein forms a homodimer composed of two interconnected subu-
nits, partly separated by an internal channel, and uniquely adapted to associate with phospholipids22. Recently, it 
was found that binding of bile acid enhances dimer assembly, and stimulates the NAPEPLD enzyme to favor the 
selective production of the endocannabinoid anandamide and other fatty acid ethanolamides23.
Mice with a targeted disruption of the NAPEPLD gene were viable and healthy, but displayed reductions in 
very long-chain saturated and mono-unsaturated N-acyl ethanolamines in the central nervous system24. Brain 
tissue from mice lacking GDE1 and NAPEPLD showed a near-complete loss in N-acyl-phosphatidylethanolamine 
conversion to N-acyl ethanolamines, but bulk brain levels of N-acyl ethanolamines were unaltered25. It was con-
cluded that, both GDE1 and NAPEPLD make partial contributions to the biosynthesis of anandamide and other 
N-acyl ethanolamines in vivo25. No brain pathology was investigated in these knock-out mice. Pharmacological 
administration of agonists and antagonists of cannabinoid receptors in rats showed that the activation of both 
receptors is needed to augment the expression of myelin basic protein in the subcortical white matter26. Although 
most studies have focused on the role of endocannabinoids in neuronal differentiation, essential data suggest 
that these signalling lipids are also important in myelination of long-range axons to increase their conductance 
velocity27. Therefore we speculate that disruption in the production of endocannabinoids by a mutation in the 
NAPELPD gene could be a mechanism of demyelination. Recently, a marked upregulation of type-2 cannabinoid 
receptors in the spinal cord of dogs showing SOD1-associated degenerative myelopathy was reported, support-
ing the assumed neuroprotective function of the endocannabinoid system in neurodegenerative disorders28. For 
the first time, our study implicates a significant role of the NAPEPLD enzyme, and thereby the endocannabi-
noid system, in maintaining the white matter. In LEMP-affected dogs it was previously speculated that the pri-
mary defect might be located in neurons or axons13. Therefore the NAPEPLD enzyme could be involved in the 
axon-myelin crosstalk and might improve the understanding of the currently poorly characterized molecular 
and cellular mechanisms that impact the differentiation of oligodendrocytes and myelination29. Furthermore, 
there is as yet no association known for involvement of the NAPEPLD gene in myelin disorders in people19. The 
group of heterogeneous leukoencephalopathies, characterized by white matter abnormalities affecting the CNS, 
is associated with various genes; still, the genetic cause in about every second patient is unknown30,31. We suggest 
the NAPEPLD gene is worthy of investigation as a possible molecular basis of genetic leukoencephalopathies.
There are 173 observed human NAPEPLD coding region variants depicted in Exac Browser32: 43 are synony-
mous, 123 are missense, and 4 are loss of function; with 3 CNVs. The synonymous, missense and CNV variants all 
have positive Z scores, indicating increased intolerance to variation and fewer variants in the gene than expected. 
The probability of loss of function intolerance is pLI = 0.06, which places NAPEPLD gene variants as most likely 
being recessive, where heterozygous loss of function variants are often tolerated32. One missense human SNP 
(rs367936558) alters the same position of the human NAPEPLD protein as the variant found in Leonbergers; 
however the alanine residue is exchanged by valine (p.Ala180Val), not by proline as found here. This human vari-
ant is present in only 1 out of 60,704 patients, and in heterozygous state (allele frequency of 8.237e−06)32.
The two disease-associated canine NAPEPLD variants affect the highly conserved metallo-beta-lactamase 
domain: changing a single amino acid in LEMP-affected Leonbergers, and removing the entire domain by a 
frameshift in Rottweilers. Interestingly, with the exception of two dogs, the general disease phenotype in these two 
breeds is very similar, although we have noticed a certain variability comparing dogs within the affected breeds shar-
ing the identical homozygous mutant genotype. This could be explained either by disease progression over time, 
or by the individual genetic background and epistatic effects to unknown variation in possible modifier genes33. 
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Recently it was shown that variations in SP110-mediated gene transcription may underlie, at least in part, the var-
iability in risk for developing canine degenerative myelopathy among Pembroke Welsh Corgis that are homozy-
gous for the disease-related SOD1 mutation34. Similar efforts might be carried out to identify modifier genes 
explaining the observed variability in developing LEMP in Leonbergers. In addition, by genotyping several thou-
sand Leonbergers, we noticed about 1% of dogs harboring the homozygous mutant genotype with no reported 
clinical manifestation (Table 1). This indicates a reduced penetrance of the NAPEPLD missense variant and sup-
ports recent findings in human genetics indicating that incomplete penetrance for presumed Mendelian diseases 
is likely more common than previously believed35.
Furthermore, the neuropathological examination of eight NAPEPLD homozygous mutant Leonbergers 
indicated that one dog had a primary axonal disorder, not a myelin disorder, which was first noticed clini-
cally as late as 7.5 years of age (Leonberger case L8, Supplementary Table S1). As we have learned recently in 
polyneuropathy-affected Leonbergers, where only approximately every third polyneuropathy-diagnosed 
Leonberger can be explained by the reported ARHGEF10 or GJA9 variants36,37, this case could possibly be 
explained by an independent mutation in an unknown gene causing polyneuropathy, although a possible effect of 
the NAPEPLD genotype could not be ruled out. Altogether, this nicely highlights the limits to precisely clinically 
diagnosing neurological diseases in dogs. Furthermore, we noticed in Leonbergers that some dogs were initially 
diagnosed as polyneuropathy-affected, although in fact they were suffering from LEMP. Disease awareness has to 
be taken into account as well, when dogs that have not been diagnosed by a board-certified neurologist are used 
for genetic studies. Finally, variation in histopathological phenotypes and genotype-phenotype correlations in the 
population may also be influenced by the fact that the samples available were examined retrospectively from dogs 
of varying age and geographic locations.
In the Rottweilers it is unclear whether the truncated NAPEPLD protein produced by the frameshift variant, 
with more than 70% of the normal protein missing, is actually expressed. Furthermore, it is very unlikely that 
the predicted mutant protein with a recoded peptide of 186 amino acids before the newly encoded stop codon, 
without any sequence similarity to the normal protein (Supplementary Fig. S6), would fulfill any physiologi-
cal function. This mutant protein would also have the functionally important metallo-beta-lactamase domain 
missing (Fig. 3). It is therefore more likely that the mutant mRNA is targeted by non-sense-mediated decay, thus 
the deleterious canine NAPEPLD variant represents the most likely causative variant in the four LEMP-affected 
Rottweilers.
Our results provide strong evidence for allelic heterogeneity in canine LEMP, where two independent 
NAPEPLD variants were found in Leonbergers and Rottweilers. In addition, we found several Great Danes 
being heterozygous carriers of the variant identified in Rottweilers, but so far we have not seen a homozygous 
mutant dog in this third breed. Although all three breeds are part of the Molossian section of the World Canine 
Organization classification, Leonbergers belong to the Mountain type dogs, and both Rottweilers and Great 
Danes represent the group of Mastiff type dogs. According to a recent study on the development of modern 
dog breeds all three breeds belong to separate clades, but show significant haplotype sharing38. This example of 
a similar canine disease occurring in different breeds caused by independent variants affecting the same gene, 
is comparable to what has been shown before, for example, in canine NDRG1-related polyneuropathy (OMIA 
002120-9615)39,40. The missense variant detected in Leonbergers is probably caused by a recent mutation event as 
the associated haplotype encompasses a 0.9-Mb-sized region. On the other hand, the frameshift variant detected 
in LEMP-affected Rottweilers and in Great Dane carriers most likely has a quite old origin, as it exists on a rela-
tively small-sized common haplotype of 50 kb.
In conclusion, here we report the identification of two NAPEPLD-associated variants in LEMP-affected dogs. 
Our results indicate a recessive mode of inheritance in each, albeit with a slightly reduced penetrance, and enable 
the development of genetic tests for veterinary diagnostic and breeding purposes. Our study describes a canine 
neurological disease with distinctive pathological features and implicates the NAPEPLD protein as an important 
enzyme in myelin homeostasis. Finally, our results reveal a novel candidate gene for myelin disorders such as the 
genetic leukoencephalopathies in humans.
Methods
Animals. Written consent was obtained from all dogs’ owners. Dog samples were obtained primarily via elec-
tive owner submission for diagnostic purposes or were submitted for genotyping of the previously reported pol-
yneuropathy-associated variants in Leonbergers. Most of these dogs do not have complete medical information 
and were used only for a population study. Blood collection from dogs does not require anesthesia and the study 
was approved according to the national guidelines for animal welfare by the Institutional Animal Care and Use 
Committees (IACUC) of the University of Minnesota, and by the Cantonal Committee for Animal Experiments 
(Canton of Bern; permits 23/10, 48/13 and 75/16) for the University of Bern.
All invasive procedures were performed post-mortem either on animals that had died of natural causes, or after 
euthanasia, thus no ethical evaluation was required. All methods were performed in accordance with the relevant 
guidelines and regulations of the University of Minnesota and the University of Bern.
Genomic DNA was isolated from blood using either the Gentra PureGene blood kit (Qiagen) or the Maxwell 
RSC whole blood DNA kit (Promega). The phenotypic characterization of LEMP in Leonbergers and Rottweilers 
has been described elsewhere and the previously established criteria to select cases and controls were applied36. 
Samples from a total of 7,086 Leonbergers, including 213 dogs with detailed phenotype records (Supplementary 
Table S1), and 233 Rottweilers, including four dogs with detailed phenotype records (Supplementary Table S4) 
were used during this study. All Leonbergers were genotyped for the polyneuropathy-associated ARHGEF10 and 
GJA9 variants as previously described36,37 to test for underlying neurological disease. Furthermore, DNA samples 
of 262 Great Danes, 47 St. Bernards, 10 Newfoundlands, 10 Entlebucher Mountain dogs, 8 Appenzeller Mountain 
dogs, 7 Bernese Mountain dogs, and 6 Greater Swiss Mountain dogs were taken from the Vetsuisse Biobank.
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Histopathology. Histopathological samples of eight Leonbergers and four Rottweilers were examined. Two 
to five µm thick sections from 10% neutral-buffered formalin fixed and paraffin-embedded brain and spinal cord 
were retrieved from histopathological archives of different diagnostic labs. These included combined luxol fast 
blue/hematoxylin and eosin stained sections or combined luxol fast blue/periodic acid Schiff stained sections. In 
five cases, Bielschowsky silver stained sections and in one case sections labeled with PGP 9.5 immunohistochem-
istry were available for evaluation of axonal density. Tissue sections were examined by light microscopy.
SNP array genotyping. Genomic DNA samples of 200 Leonbergers, 10 Rottweilers, and 17 Great Danes 
were genotyped with the Illumina CanineHD BeadChip array by GeneSeek/Neogen for 173,662 SNP markers. 
In Leonbergers we performed pruning of genotyping data as described previously36 and 112,833 SNPs remained 
for genome-wide association study (GWAS). Fourteen LEMP-affected dogs and 186 controls (i. e. dogs eight 
years and older that showed no signs of neurological disease) were analyzed with the mixed model from the 
GenABEL library41 and the hglm package42 in the R environment that corrects for the population stratification. 
Multidimensional scaling analysis was carried with the GenABEL41. We used 173k SNP data of additional 147 
Rottweilers as controls, which were publically available from previous projects43,44, to perform GWAS. Due to the 
limited number of cases in Rottweilers, only a fast score test (GenABEL) for association corrected for possible 
stratification by principal components was performed. Haplotypes around the significantly associated locus were 
constructed using fastPHASE45. All genome positions refer to the CanFam3.1 reference sequence assembly.
Whole genome sequencing. We performed a whole-genome sequencing of a LEMP-affected Leonberger. 
Briefly, we prepared a fragment library with 300 bp insert size and collected ~200 million 2 × 100 bp paired-end 
reads on a HiSeq. 2000 instrument (Illumina, San Diego, USA), which corresponds to roughly 17x coverage. The 
reads were mapped against the dog reference genome assembly (CanFam3.1) as described before36. The anno-
tation version CanFam3.1.75 (http://www.ensembl.org) was used to predict the functional effects of detected 
variants as described previously36. In addition, whole-genome sequencing of a LEMP-affected Rottweiler (case 
R2; 13× coverage) was performed accordingly.
The IGV-viewer software46 was used for visual inspection of sequence variants to exclude any structural var-
iants in the critical region. For variant filtering we used 204 control genomes, which were either publicly availa-
ble47 or produced during other projects of our group. A list of these control genomes is given in Supplementary 
Table S2.
Gene analysis. We used the dog CanFam 3.1 reference genome assembly for all genomic analyses. The chro-
mosome 18 reference sequence has a gap after NAPEPLD exon 4 and does not include exon 5 (Supplementary 
Fig. S7). A partial sequence of intron 3, the entire exon 4, intron 4 and exon 5 are retrievable on the unplaced con-
tig Un_JH373889 of the CanFam 3.1 assembly (Supplementary Fig. S7). Numbering within the canine NAPEPLD 
transcript corresponds to the mRNA sequences within study accession PRJEB22251. The predicted effects of the 
mutations were evaluated by PolyPhen248, SIFT49, Mutation Taster50, and MutPred251.
RNA-seq. We isolated total RNA from spinal cord samples from a single LEMP-affected Leonberger and a 
Labrador control using the RNeasy Fibrous Tissue Mini kit (Qiagen). Prior to RNA extraction, the tissue was 
mechanically disrupted using the TissueRuptor device (Qiagen). The RNA samples were transformed into 
Illumina TruSeq libraries and 2 × 150 bp sequencing reads were obtained on a HiSeq3000 instrument (Illumina). 
RNA-seq data analysis was done as described before52.
Sanger sequencing. We used Sanger sequencing to confirm the candidate NAPEPLD variant c.538 G > C 
in the affected Leonberger and to amplify the coding exons of the NAPEPLD gene in the affected Rottweilers. We 
amplified PCR products (primers are shown in Supplementary Table S5) using AmpliTaqGold360Mastermix 
(Life Technologies) and purified PCR products were directly sequenced on an ABI3730 capillary sequencer (Life 
Technologies). The sequence data were analyzed using Sequencher 5.1 software (GeneCodes).
Data Availability. Genome sequencing data were deposited in the European Nucleotide Archive (ENA, 
http://www.ebi.ac.uk/ena): The LEMP-affected Leonberger (sample accession number SAMEA103935360 within 
study accession PRJEB16012) and the LEMP-affected Rottweiler (sample accession number SAMEA3121337 
within study accession PRJEB7735). RNAseq data were deposited in the ENA under sample accession number 
SAMEA103936001 within study accession PRJEB20118. The mRNA sequences for the canine N-acyl phosphati-
dylethanolamine phospholipase D (NAPEPLD) gene were deposited in the ENA under sample accession number 
LT906616 and LT906617 within study accession PRJEB22251.
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